Multiple myeloma—A painful disease of the bone marrow

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Multiple myeloma—A painful disease of the bone marrow. / Diaz-delcastillo, Marta; Chantry, Andrew D.; Lawson, Michelle A.; Heegaard, Anne-marie.

In: Seminars in Cell and Developmental Biology, Vol. 112, 2021, p. 49-58.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Diaz-delcastillo, M, Chantry, AD, Lawson, MA & Heegaard, A 2021, 'Multiple myeloma—A painful disease of the bone marrow', Seminars in Cell and Developmental Biology, vol. 112, pp. 49-58. https://doi.org/10.1016/j.semcdb.2020.10.006

APA

Diaz-delcastillo, M., Chantry, A. D., Lawson, M. A., & Heegaard, A. (2021). Multiple myeloma—A painful disease of the bone marrow. Seminars in Cell and Developmental Biology, 112, 49-58. https://doi.org/10.1016/j.semcdb.2020.10.006

Vancouver

Diaz-delcastillo M, Chantry AD, Lawson MA, Heegaard A. Multiple myeloma—A painful disease of the bone marrow. Seminars in Cell and Developmental Biology. 2021;112:49-58. https://doi.org/10.1016/j.semcdb.2020.10.006

Author

Diaz-delcastillo, Marta ; Chantry, Andrew D. ; Lawson, Michelle A. ; Heegaard, Anne-marie. / Multiple myeloma—A painful disease of the bone marrow. In: Seminars in Cell and Developmental Biology. 2021 ; Vol. 112. pp. 49-58.

Bibtex

@article{05cd5b2c1ffb48d1933306edea21ec4d,
title = "Multiple myeloma—A painful disease of the bone marrow",
abstract = "Multiple myeloma is a bone marrow neoplasia with an incidence of 6/100,000/year in Europe. While the disease remains incurable, the development of novel treatments such as autologous stem cell transplantation, proteasome inhibitors and monoclonal antibodies has led to an increasing subset of patients living with long-term myeloma. However, more than two thirds of patients suffer from bone pain, often described as severe, and knowledge on the pain mechanisms and its effect on their health-related quality of life (HRQoL) is limited. In this review, we discuss the mechanisms of myeloma bone disease, the currently available anti-myeloma treatments and the lessons learnt from clinical studies regarding HRQoL in myeloma patients. Moreover, we discuss the mechanisms of cancer-induced bone pain and the knowledge that animal models of myeloma-induced bone pain can provide to identify novel analgesic targets. To date, information regarding bone pain and HRQoL in myeloma patients is still scarce and an effort should be made to use standardised questionnaires to assess patient-reported outcomes that allow inter-study comparisons of the available clinical data.",
author = "Marta Diaz-delcastillo and Chantry, {Andrew D.} and Lawson, {Michelle A.} and Anne-marie Heegaard",
year = "2021",
doi = "10.1016/j.semcdb.2020.10.006",
language = "English",
volume = "112",
pages = "49--58",
journal = "Seminars in Cell and Developmental Biology",
issn = "1084-9521",
publisher = "Academic Press",

}

RIS

TY - JOUR

T1 - Multiple myeloma—A painful disease of the bone marrow

AU - Diaz-delcastillo, Marta

AU - Chantry, Andrew D.

AU - Lawson, Michelle A.

AU - Heegaard, Anne-marie

PY - 2021

Y1 - 2021

N2 - Multiple myeloma is a bone marrow neoplasia with an incidence of 6/100,000/year in Europe. While the disease remains incurable, the development of novel treatments such as autologous stem cell transplantation, proteasome inhibitors and monoclonal antibodies has led to an increasing subset of patients living with long-term myeloma. However, more than two thirds of patients suffer from bone pain, often described as severe, and knowledge on the pain mechanisms and its effect on their health-related quality of life (HRQoL) is limited. In this review, we discuss the mechanisms of myeloma bone disease, the currently available anti-myeloma treatments and the lessons learnt from clinical studies regarding HRQoL in myeloma patients. Moreover, we discuss the mechanisms of cancer-induced bone pain and the knowledge that animal models of myeloma-induced bone pain can provide to identify novel analgesic targets. To date, information regarding bone pain and HRQoL in myeloma patients is still scarce and an effort should be made to use standardised questionnaires to assess patient-reported outcomes that allow inter-study comparisons of the available clinical data.

AB - Multiple myeloma is a bone marrow neoplasia with an incidence of 6/100,000/year in Europe. While the disease remains incurable, the development of novel treatments such as autologous stem cell transplantation, proteasome inhibitors and monoclonal antibodies has led to an increasing subset of patients living with long-term myeloma. However, more than two thirds of patients suffer from bone pain, often described as severe, and knowledge on the pain mechanisms and its effect on their health-related quality of life (HRQoL) is limited. In this review, we discuss the mechanisms of myeloma bone disease, the currently available anti-myeloma treatments and the lessons learnt from clinical studies regarding HRQoL in myeloma patients. Moreover, we discuss the mechanisms of cancer-induced bone pain and the knowledge that animal models of myeloma-induced bone pain can provide to identify novel analgesic targets. To date, information regarding bone pain and HRQoL in myeloma patients is still scarce and an effort should be made to use standardised questionnaires to assess patient-reported outcomes that allow inter-study comparisons of the available clinical data.

U2 - 10.1016/j.semcdb.2020.10.006

DO - 10.1016/j.semcdb.2020.10.006

M3 - Journal article

C2 - 33158730

VL - 112

SP - 49

EP - 58

JO - Seminars in Cell and Developmental Biology

JF - Seminars in Cell and Developmental Biology

SN - 1084-9521

ER -

ID: 257200446